Zoetis (NYSE:ZTS) Posts Earnings Results

Zoetis (NYSE:ZTS) announced its earnings results on Thursday. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03, Zacks reports. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis updated its FY 2025 guidance to 6.000-6.100 EPS.

Zoetis Trading Down 7.1 %

Shares of Zoetis stock traded down $12.37 during trading on Thursday, hitting $161.51. 7,914,538 shares of the company were exchanged, compared to its average volume of 2,800,073. The firm has a market capitalization of $72.87 billion, a P/E ratio of 30.31, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. Zoetis has a 1-year low of $144.80 and a 1-year high of $200.53. The firm’s fifty day moving average price is $169.08 and its 200 day moving average price is $179.08. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.24%. Zoetis’s payout ratio is currently 37.59%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Morgan Stanley lowered their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus price target of $214.00.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.